VYNE Therapeutics (VYNE) Price & Analysis

Compare

1,887 Followers

VYNE Stock Chart & Stats

$0.35

-$0.38(-8.88%)

At close: Jan 08 4:00 PM EST

$0.35

-$0.38(-8.88%)

Day’s Range― - ―

52-Week Range$0.28 - $4.30

Previous CloseN/A

Volume117.27K

Average Volume (3M)2.75M

Market Cap

$8.34M

Enterprise Value$30.93M

Total Cash (Recent Filing)$32.70M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.13

Next Earnings

Feb 26, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding25,472,164

10 Day Avg. Volume3,707,448

30 Day Avg. Volume2,746,500

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)2.74

Price to Sales (P/S)284.78

P/FCF Ratio-4.19

Enterprise Value/Market Cap3.71

Enterprise Value/Revenue59.03

Enterprise Value/Gross Profit368.22

Enterprise Value/Ebitda-0.84

Forecast

1Y Price Target

$2.00

Price Target Upside471.43% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsVYN202 showed clean safety and tolerability, with no adverse events associated with BET inhibition, encouraging further development in other serious autoimmune diseases.

FDA ApprovalThe FDA lifted the clinical hold on 0.25 and 0.5mg doses of VYN202 for female patients, offering encouraging proof-of-concept for VYN202 and highlighting its potential across various autoimmune indications.

Preclinical DataVYN202 has demonstrated promising preclinical data across multiple models of fibro-inflammatory disease and hematologic malignancies.

Bears Say

Clinical Trial FailureThe Phase IIb study evaluating repibresib gel in nonsegmental vitiligo did not meet its primary or key secondary endpoint.

High Discontinuation RateThe study of repibresib was impacted by a higher-than-expected vehicle effect and discontinuation rate, leading to the termination of the extension phase of the trial.

Stock DowngradeAnalyst downgrades VYNE from Buy to NEUTRAL as they await additional updates from management.

VYNE Therapeutics News

VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year

Reports Q3 revenue $169k vs $121k last year. “Consistent with our focus on growing shareholder value, we have...

3d ago

VYNE

VYNE Therapeutics Reports Q3 2025 Financial Results

Vyne Therapeutics Inc ( ($VYNE) ) has released its Q3 earnings. Here is a breakdown of the information...

2d ago

VYNE

VYNE Therapeutics Faces Nasdaq Non-Compliance Notice

VYNE Therapeutics ( ($VYNE) ) has shared an update. On September 11, 2025, VYNE Therapeutics received a notification...

2M ago

VYNE

VYNE Therapeutics Reports Q2 2025 Financials and Updates

Vyne Therapeutics Inc ( ($VYNE) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

VYNE

VYNE Therapeutics: Hold Rating Amid Mixed Clinical Outcomes and Financial Sustainability

LifeSci Capital analyst Rami Katkhuda has maintained their neutral stance on VYNE stock, giving a Hold rating on...

3M ago

VYNE

VYNE Therapeutics Directors Resign Amid Financial Updates

An announcement from VYNE Therapeutics ( ($VYNE) ) is now available. On August 11 and 13, 2025, Christine...

3M ago

VYNE

VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year

Reports Q2 revenue $69,000 vs $198,000 last year. “The strength of our recent clinical and preclinical findings for...

3M ago

VYNE

VYNE Earnings this Week: How Will it Perform?

Vyne Therapeutics Inc (VYNE) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street...

3M ago

VYNE

Watch Out! Analysts Have Recently Downgraded These Stocks

As an investor, it is prudent to keep track of stocks that have been downgraded by Wall Street,...

3M ago

AMD

NEO

Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?

VYNE Therapeutics stock plummeted on Wednesday after a Phase 2b trial missed its primary endpoint. ...

3M ago

VYNE

VYNE Therapeutics downgraded to Neutral from Buy at BTIG

BTIG analyst Julien Harrison downgraded VYNE Therapeutics (VYNE) to Neutral from Buy with no price target after the...

3M ago

VYNE

VYNE Therapeutics: Buy Rating Supported by Promising VYN202 Prospects Amidst Challenges

Analyst Stacy Ku of TD Cowen maintained a Buy rating on VYNE Therapeutics, with a price target of...

3M ago

VYNE

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports and more have the stock market on the move today, and TipRanks has the latest highlights! ...

3M ago

VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss

H.C. Wainwright downgraded VYNE Therapeutics (VYNE) to Neutral from Buy and removed the firm’s prior $4.50 price target...

3M ago

VYNE

VYNE FAQ

What was VYNE Therapeutics’s price range in the past 12 months?

VYNE Therapeutics lowest stock price was $0.28 and its highest was $4.30 in the past 12 months.

What is VYNE Therapeutics’s market cap?

VYNE Therapeutics’s market cap is $8.34M.

When is VYNE Therapeutics’s upcoming earnings report date?

VYNE Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 109 days.

How were VYNE Therapeutics’s earnings last quarter?

VYNE Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.173 by $0.003.

Is VYNE Therapeutics overvalued?

According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does VYNE Therapeutics pay dividends?

VYNE Therapeutics does not currently pay dividends.

What is VYNE Therapeutics’s EPS estimate?

VYNE Therapeutics’s EPS estimate is -0.15.

How many shares outstanding does VYNE Therapeutics have?

VYNE Therapeutics has 25,472,164 shares outstanding.

What happened to VYNE Therapeutics’s price movement after its last earnings report?

VYNE Therapeutics reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.173. Following the earnings report the stock price went up 4.748%.

Which hedge fund is a major shareholder of VYNE Therapeutics?

Currently, no hedge funds are holding shares in VYNE

Company Description

VYNE Therapeutics

VYNE Therapeutics (VYNE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with dermatological, autoimmune, and other inflammatory conditions. The company utilizes its proprietary technology platforms to create novel drug candidates aimed at addressing significant unmet medical needs. VYNE's core products include its leading investigational therapies, which are designed to improve treatment outcomes for patients suffering from chronic skin disorders and related ailments.

VYNE Therapeutics (VYNE) Earnings & Revenues

Historic Earnings Reports

VYNE Stock 12 Month Forecast

Average Price Target

$2.00

▲(471.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.355,0.4815384615384615,0.6080769230769231,0.7346153846153847,0.8611538461538462,0.9876923076923076,1.1142307692307694,1.2407692307692308,1.3673076923076923,1.4938461538461538,1.6203846153846153,1.746923076923077,1.8734615384615385,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.355,0.4815384615384615,0.6080769230769231,0.7346153846153847,0.8611538461538462,0.9876923076923076,1.1142307692307694,1.2407692307692308,1.3673076923076923,1.4938461538461538,1.6203846153846153,1.746923076923077,1.8734615384615385,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.355,0.4815384615384615,0.6080769230769231,0.7346153846153847,0.8611538461538462,0.9876923076923076,1.1142307692307694,1.2407692307692308,1.3673076923076923,1.4938461538461538,1.6203846153846153,1.746923076923077,1.8734615384615385,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.928,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.352,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.339,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.355,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >